Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.
Coordinated growth of the skull and brain are vital to normal human development. Craniosynostosis, the premature fusion of the calvarial bones of the skull, is a relatively common pediatric disease, occurring in 1 in 2500 births, and requires significant surgical management, especially in syndromic cases. Syndromic craniosynostosis is caused by a variety of genetic lesions, most commonly by activating mutations of FGFRs 1-3, and inactivating mutations of TWIST1. In a mouse model of TWIST1 haploinsufficiency, cell mixing between the neural crest-derived frontal bone and mesoderm-derived parietal bone accompanies coronal suture fusion during embryonic development. However, the relevance of lineage mixing in craniosynostosis induced by activating FGFR mutations is unknown. Here, we demonstrate a novel mechanism of suture fusion in the Apert Fgfr2(S252W) mouse model. Using Cre/lox recombination we simultaneously induce expression of Fgfr2(S252W) and β-galactosidase in either the neural crest or mesoderm of the skull. We show that mutation of the mesoderm alone is necessary and sufficient to cause craniosynostosis, while mutation of the neural crest is neither. The lineage border is not disrupted by aberrant cell migration during fusion. Instead, the suture mesenchyme itself remains intact and is induced to undergo osteogenesis. We eliminate postulated roles for dura mater or skull base changes in craniosynostosis. The viability of conditionally mutant mice also allows post-natal assessment of other aspects of Apert syndrome.
Department of Microbiology, New York University School of Medicine, 550 1st Ave, New York, NY 10016, USA. gregory.holmes@exchange.mssm.edu
Greg
G
Holmes
Claudio
C
Basilico
D000168:Acrocephalosyndactylia / Q000235:genetics / Q000378:metabolism; D019943:Amino Acid Substitution; D000818:Animals; D000831:Animals, Newborn; D003393:Cranial Sutures / Q000196:embryology / Q000254:growth & development / Q000378:metabolism; D003398:Craniosynostoses / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D018507:Gene Expression Regulation, Developmental; D006651:Histocytochemistry; D006801:Humans; D008648:Mesoderm / Q000196:embryology / Q000254:growth & development / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009154:Mutation; D009432:Neural Crest / Q000196:embryology / Q000254:growth & development / Q000378:metabolism; D010012:Osteogenesis / Q000235:genetics; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics / Q000378:metabolism*; D001616:beta-Galactosidase / Q000235:genetics / Q000378:metabolism
C496354:Fgfr2 protein, mouse; D051497:Receptor, Fibroblast Growth Factor, Type 2; D001616:beta-Galactosidase